Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEXX Laboratories, Inc. (IDXX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed, S&P 500 company focused on pet healthcare innovation, veterinary diagnostics, and software, IDEXX uses SEC filings to report financial results, material agreements, and governance changes that matter to shareholders and analysts.
Among the most closely watched documents are annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which describe IDEXX’s business, risk factors, and detailed financial statements, including performance in areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Current reports on Form 8‑K provide timely updates on specific events, such as quarterly earnings releases, amendments to credit agreements, and board or leadership changes. For example, IDEXX has filed 8‑Ks describing an amendment to a credit agreement that provides unsecured revolving and term loan facilities for general corporate purposes, as well as filings that furnish earnings press releases.
Investors can also use this page to monitor proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports when available, which show purchases and sales of IDXX shares by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users navigate lengthy documents such as 10‑Ks and 10‑Qs. Real-time updates from EDGAR mean new IDEXX filings appear promptly, while AI highlights important items like changes in leverage arrangements, governance updates, and trends in reported results. This makes it easier to understand how IDEXX’s regulatory disclosures relate to its veterinary diagnostics, software, and animal health businesses.
IDEXX Laboratories reported solid growth for the quarter ended March 31, 2026. Total revenue rose to $1.14 billion from $998.4 million a year earlier, driven mainly by higher Companion Animal Group diagnostic and software revenues and broader international demand.
Net income increased to $278.4 million from $242.7 million, with diluted earnings per share up to $3.47 from $2.96. Operating cash flow was strong at $266.2 million, supporting continued investment and capital returns, including $360.8 million of open-market share repurchases and ongoing use of the company’s credit facility and senior notes.
IDEXX Laboratories reported strong first quarter 2026 results, with revenue of $1.14 billion, up 14% as reported and 11% organically. Growth was led by Companion Animal Group revenue, including 14% reported and 11% organic CAG Diagnostics recurring revenue growth, and 33% reported growth in diagnostics capital instruments.
Diluted EPS was $3.47, up 17% as reported and 15% on a comparable basis. Gross margin improved to 63.4% and operating margin to 31.8%. Free cash flow was $234 million. Management raised full-year 2026 guidance, targeting revenue of $4.675–$4.760 billion, organic growth of 7.7%–9.7%, and EPS of $14.45–$14.90.
IDEXX Laboratories director Joseph L. Hooley acquired 43 deferred stock units tied to the company’s common stock as a compensation award. The units were valued using a reference price of $560.80 per share, reflecting the conversion of $24,375.00 of cash compensation he chose to defer.
Each deferred stock unit represents the right to receive one IDEXX share in the future. The units vest immediately and will be settled in stock after Hooley leaves the Board or on another fixed date allowed under the director plan. Following this grant, he directly holds 118 deferred stock units.
IDEXX Laboratories Inc reported that Vanguard Capital Management beneficially owns 5,976,472 shares of Common Stock, representing 7.51% of the class. The filer reports sole dispositive power over 5,976,472 shares and sole voting power over 793,965 shares. The filing states the ownership reflects securities held by Vanguard affiliates and funds and is signed by Ashley Grim, Head of Global Fund Administration.
IDEXX Laboratories presents its 2026 proxy, highlighting strong 2025 growth, major product launches, an upcoming CEO transition and several governance proposals. Revenue reached $4.3B, up 10%, with operating profit of $1.4B and diluted EPS of $13.08, a 23% increase, supported by margin expansion and resilient demand despite lower U.S. vet visit volumes.
The company underscores innovation such as IDEXX Cancer Dx for early canine cancer detection, the inVue Dx cellular analyzer and the ImageVue DR50 Plus imaging system. Shareholders will vote on director elections, auditor ratification, executive pay, declassifying the Board, a 25% special-meeting right and a separate special-meeting shareholder proposal the Board opposes.
IDEXX Laboratories Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately in reliance on SEC Release No. 34-39538.
IDEXX Laboratories announced that Executive Vice President, Global Strategy and Commercial, Nimrata Hunt, PhD, will leave her role effective April 13, 2026, then serve as a special advisor on an as‑needed basis until July 13, 2026.
Under a separation agreement, IDEXX will provide salary continuation for 104 weeks totaling $1,230,000 and pay her target annual bonus for two years totaling $984,000, alongside a $50,000 COBRA-related lump sum, $10,000 in transition assistance and up to $6,000 per year for 2025 and 2026 tax or financial planning services.
Unvested stock options, restricted stock units and performance stock units will be forfeited as of the final employment date, while vested stock options remain exercisable under existing award terms. IDEXX characterizes the move as a termination without cause tied to elimination of her position and obtained a broad release, non‑disparagement and ongoing cooperation commitments.
IDEXX Laboratories, Inc. presents its preliminary 2026 Proxy Statement summarizing 2025 performance, corporate priorities and governance matters.
The company reports $4.3B revenue, $13.08 diluted EPS, 10% reported revenue growth and highlights innovation milestones and a planned CEO transition effective upon adjournment of the 2026 Annual Meeting on May 12, 2026.
IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026. The option conversion resulted in 197 shares of common stock at a transaction price of 505.5300 per share, bringing her direct common stock holdings to 7,137.654 shares.
The incentive stock option right-to-buy covered 197 shares and, following the exercise, showed 0 derivative shares remaining. A footnote states the option grant to buy issuer common stock vested on February 14, 2026, indicating this was a scheduled equity award exercise.